Ergot and Oxytocin During Cesarean Delivery Following Failure to Progress in Labour
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
Despite of marked improvements in clinical management, early postpartum
hemorrhage(PPH)remains a significant contributor to maternal morbidity and mortality both in
developing countries and in hospitals equipped with all that modern medicine has to offer.
This complication is amongst the most challenging that a clinician will face in the obstetric
patient. Prevention, early recognition and prompt appropriate intervention are the keys to
minimizing the impact of PPH on women's health.
Patients undergoing Cesarean sections following failure to progress in labor are at great
risk for PPH and should theoretically benefit from an additional uterotonic agent. This study
will be conducted to define whether the addition of ergonovine maleate to oxytocin,
administered in a prophylactic way, reduces blood loss during Cesarean section for failure to
progress in labor.
Phase:
N/A
Details
Lead Sponsor:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital